Zoetis Is Cheap, Burry's In, and I Still Wouldn't Touch It Before Thursday

# Zoetis Is Cheap, Burry's In, and I Still Wouldn't Touch It Before Thursday

Here's a fun game: take a wide-moat, 37%-operating-margin, 67%-ROE animal health monopoly, cut its stock in half over twelve months, watch Michael Burry back up the truck, and ask yourself why it still can't catch a bounce. That's Zoetis right now — a genuinely great business trading like a cyclical dog, sitting at $76 the night before a binary earnings event that has burned longs twice already this year.

Let's rewind the tape. Zoetis walked into 2026 guiding above Street estimates in February. Shares still dropped 5% because management admitted the U.S. companion-animal business "remains" under pressure — the market smelled smoke before there was fire. Then in May, the fire arrived: Q1 EPS of $1.53 missed the $1.61 consensus, revenue growth flatlined on an organic basis, and Zoetis slashed full-year guidance, blaming a "more challenging operating environment," price-sensitive pet owners, and sharper competition. The stock got torched. It's now down roughly 50% from its $160 high and parked six percent above its 52-week low. That's not a dip. That's a re-rating.

The bull case writes itself, and it's not wrong. This is still the dominant animal health franchise on the planet — 71.8% gross margins, 36.6% operating margins, $1.78 billion in free cash flow, a 2.75% dividend yield with a comfortable 33.7% payout ratio, and secular tailwinds (pet humanization, global protein demand) that don't care about quarterly guidance cuts. At 10.3x forward earnings and a PEG of 1.39, this is priced like a company in structural decline, not one with a wide moat and a 12-candidate pipeline including new OA monoclonal antibodies already launching in Canada and the EU. Next-year EPS growth estimates just jumped from 7.1% to 12.2% — the first positive fundamental signal in months. Add Burry doubling down publicly this week, and you've got a textbook "smart money buying the blood" narrative.

Here's the part the bulls keep glossing over. Revenue has now stepped down four quarters straight — $2.46B, $2.40B, $2.39B, $2.26B — and operating income has compressed right alongside it, from $989M to $822M. That's not noise, that's a trend. And the balance sheet is genuinely ugly: total debt of $9.24 billion against equity that shrank from $5.4 billion to $3.23 billion in two quarters, because Zoetis has been funding buybacks with debt while the equity base gets hollowed out. Debt-to-equity now sits at 2.86x. That's a leveraged bet on a stabilization story that hasn't stabilized yet.

And the chart agrees with the skeptics, not the bargain hunters. Zoetis has been stuck in a tight $72–$80 range since the May gap-down, with flat moving averages and a 200-day still sitting 31% overhead — an intact, untested downtrend. Every bounce attempt toward $100 has failed to print. This is a stock the market keeps trying to buy and keeps deciding not to hold.

So what do you do with a name that's cheap on every fundamental screen but technically dead in the water, one day before a report that could either confirm stabilization or trigger guidance cut number two? You wait. Zoetis reports before the bell Thursday, and consensus wants roughly $1.84–$1.85 in EPS on about $2.5 billion in revenue. If management can show the U.S. companion-animal business is actually flattening out — not just talking about it — this stock has every reason to re-rate hard off a 10x multiple. If it doesn't, the "cheap" argument gets cheaper, and Burry's conviction becomes an early entry rather than a well-timed one.

This is a wide-moat business trading at a discount for a reason, and that reason gets a verdict on Thursday morning. Own it if you already do. Add size into it tonight, and you're not investing — you're gambling on a coin flip that's burned this exact playbook twice in the last six months.